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Objective: To perform an extensive search for ge-
nomic rearrangements by microarray-based compara-
tive genomic hybridization in patients with epilepsy.
Design: Prospective cohort study.
Setting: Epilepsy centers in Italy.
Patients: Two hundred seventy-nine patients with un-
explained epilepsy, 265 individuals with nonsyndromic
mental retardation but no epilepsy, and 246 healthy con-
trol subjects were screened by microarray-based com-
parative genomic hybridization.
MainOutcomesMeasures: Identification of copy num-
ber variations (CNVs) and gene enrichment.
Results: Rare CNVs occurred in 26 patients (9.3%) and
16healthycontrol subjects (6.5%) (P=.26).TheCNVs iden-
tified in patients were larger (P=.03) and showed higher
gene content (P=.02) than those in control subjects. The
CNVs larger than1megabase (P=.002) and includingmore
than 10 genes (P=.005) occurred more frequently in pa-
tients than incontrol subjects.Ninepatients (34.6%)among
those harboring rare CNVs showed rearrangements asso-
ciated with emerging microdeletion or microduplication
syndromes. Mental retardation and neuropsychiatric fea-
tures were associated with rare CNVs (P=.004), whereas
epilepsy type was not. The CNV rate in patients with epi-
lepsy and mental retardation or neuropsychiatric features
is not different from that observed in patients withmental
retardationonly.Moreover, significant enrichment of genes
involved in ion transportwas observedwithinCNVs iden-
tified in patients with epilepsy.
Conclusions: Patients with epilepsy show a significantly
increased burden of large, rare, gene-rich CNVs, particu-
larly when associated with mental retardation and neuro-
psychiatric features. The limitedoverlapbetweenCNVsob-
served in theepilepsygroupand thoseobserved in thegroup
withmental retardation only as well as the involvement of
specific (ion channel) genes indicate a specific association
between the identified CNVs and epilepsy. Screening for
CNVs should be performed for diagnostic purposes pref-
erentially in patients with epilepsy andmental retardation
or neuropsychiatric features.
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I NAPPROXIMATELY 30%TO 40%OFpatients with epilepsy, there is anunderlying cause of seizure re-currence, but it is not identifi-able in most subjects.1 Although
causative mutations have been identified
for several epilepsy syndromes, mende-
lian epilepsies account for only 1% of the
cases.2 By contrast, common epilepsies
have a complex pattern of inheritance,
likely involving combinations of variants
in different genes that have proven chal-
lenging to discover.2 Linkage and genome-
wide association studies have failed to
identify robust or unambiguous associa-
tions in large series of patients.3
Copy number variations (CNVs) are in-
creasingly recognized as a source of phe-
notypic variation among humans, and the
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implementation of genome-wide technologies such asmi-
croarray-based comparative genomic hybridization (array-
CGH) and single-nucleotide polymorphism genotyping
now allows their efficient identification.4,5 A number of
studies have recently highlighted the role of CNVs in the
etiology of various neuropsychiatric disorders.6,7 Tar-
geted and genome-wide surveys of CNVs have been also
performed in individuals with epilepsy, revealing recur-
rent deletions at 15q11.2, 15q13.3, and 16p13.11 in a
small proportion of patients with different epilepsy syn-
dromes.8-11 However, the role of nonrecurrent CNVs in
the etiology of epilepsy has not yet been evaluated in de-
tail.2,5Weperformed an array-CGH–based survey ofCNVs
in subjects with epilepsy of unknown cause.
METHODS
STUDY POPULATION
We prospectively collected records of patients with unex-
plained epilepsy referred to different centers between Septem-
ber 1, 2007, and August 31, 2009. Clinical evaluation in-
cluded general and neurological examination, familial and
personal history, electroclinical findings, 1.5-T brain mag-
netic resonance imaging, treatment schedule, and outcome. Sei-
zures and epilepsy type were defined according to interna-
tional recommendations.12 The patients’ IQs were defined
according to Diagnostic and Statistical Manual of Mental Disor-
ders, fourth edition criteria (borderline intellectual function-
ing, IQ 71-84; mild mental retardation [MR], IQ 60-70; mod-
erateMR, IQ 50-59; severeMR, IQ50).We excluded patients
with the following: (1) lesional or metabolic cause of epilepsy;
(2) signs and symptoms of epileptic encephalopathy; (3) ma-
jor congenital malformations or pathognomonic dysmor-
phisms; and (4) severe MR or major neuropsychiatric diseases
(eg, schizophrenia, tic disorders, severe mood disorder). The
ethics committee of each center approved the study, and in-
formed consent was signed by participants.
CONTROL POPULATIONS
Control populations comprised subjects with nonsyndromic
MRbut no epilepsy (control subjectswithMR) andhealthy blood
donors (healthy control subjects). Subjects withMR only were
selected from a consecutive series of cases referred to the Labo-
ratory of Genetics, Galliera Hospital, Genova, Italy, between
January 1, 2008, and December 31, 2010, and classified ac-
cording to Diagnostic and Statistical Manual of Mental Disor-
ders, fourth edition criteria. Healthy control subjects were se-
lected among adults aged 40 to 60 years through a modified
version of a structured questionnaire to exclude any seizure
disorder.13
GENETIC STUDIES
Experimental Strategy
Genomic DNA of patients and control subjects was extracted
from blood lymphocytes. Samples from patients and control
subjects were screened by the Human Genome CGHMicroar-
ray 44B kit (Agilent Technologies, Inc, Santa Clara, Califor-
nia). Identified CNVs were checked in the Database of Ge-
nomic Variants (http://projects.tcag.ca/variation/) and in a data
set of 790 control subjects with neurological disease who were
of European descent.14 We adopted a quite conservative ap-
proach and did not follow up rearrangements overlappingmore
than 50% with CNVs reported in control subjects. Validation
and parental origin of CNVs were obtained by fluorescence in
situ hybridization, higher-density array-CGH slides (Microar-
ray 244K kit; Agilent Technologies, Inc), or quantitative poly-
merase chain reaction.
Array-CGH Assay
We used array-CGH containing about 44 000 60-mer oligo-
probes covering the nonredundant genome at an average dis-
tance of approximately 43 kilobases (kb) and allowing the ge-
nome-wide survey of CNVs. Labeling and hybridization were
performed following the manufacturer’s protocol. The arrays
were scanned (Microarray Scanner G2565CA; Agilent Tech-
nologies, Inc) and analyzed by Feature Extraction version 9.5.0
software andGenomicWorkbench version 5.0.14 software (Agi-
lent Technologies, Inc). Assays showing a derivative log ratio
spread score higher than 0.3 were excluded. Detection of gains
and losseswas performedusing theAberrationDetectionMethod
2 algorithm with a moving average of 500 kb and a threshold
of 6.0. In addition, we set the minimum number of consecu-
tive probes to call CNVs at 8. The same protocol was applied
for the higher-density Microarray 244K kit (Agilent Technolo-
gies, Inc).
Fluorescence In Situ Hybridization
Bacterial artificial chromosome clones were selected accord-
ing to theUCSCGenomeBrowser hg18 assembly (http://genome
.ucsc.edu; Genome Bioinformatics Group, Center for Biomo-
lecular Science and Engineering, University of California, Santa
Cruz). Bacterial artificial chromosomeDNAwas labeled by nick
translation. Slideswere counterstainedwith antifadeVectashield
Mounting Medium with 4’,6-diamidino-2-phenylindole (Vec-
tor Laboratories, Inc, Burlingame, California). Signals were vi-
sualized on a Nikon E1000 microscope (Nikon Corp, Tokyo,
Japan) equipped with a charge-coupled device camera and Ge-
nikon image analysis software (Genikon, Plano, Texas).
Quantitative Polymerase Chain Reaction
Quantitative polymerase chain reaction was performed using
the TaqMan technology on an ABI 7500 instrument (Applied
Biosystems, Inc, Foster City, California). The copy number of
the unknown samples was normalized to an endogenous ref-
erence (RNase P gene). Locus-specific TaqMan probes were se-
lected from the Applied Biosystems database.
STATISTICAL ANALYSIS
AND BIOINFORMATICS
Sample power estimates were calculated assuming an  error
of .05 and a  error of 0.2 (ie, a power of 80%). Two-tailed un-
paired t test and Fisher exact tests were used for categorical
sample and phenotype correlations; the nonparametric Mann-
WhitneyU testwas used to evaluate numerical data. The BioMart
tool (http://www.ensembl.org/biomart) was used to retrieve the
lists of RefSeq deleted and duplicated genes in patients and con-
trol subjects. In addition, we searched for GeneOntology (GO)
annotations that are overrepresented in the group of
rearranged genes using GeneCodis version 2.0 software
(http://genecodis.dacya.ucm.es).15 This tool allows the classi-
fication of genes according to their putative biological func-
tion by screening the GO annotations included in the GO Slim
database and identifying significant enrichment of specific GO
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annotations among any set of genes by normalizing for the total
number of human genes belonging to each GO group using the
hypergeometric distribution and correcting resulting P values
for multiple hypothesis testing using the false discovery rate
correction.15 The DECIPHER database of genomic unbalances
was used for genotype-phenotype correlations (https://decipher
.sanger.ac.uk/).
RESULTS
Records from 279 patients with epilepsy (152 males),
265 control subjects with MR (117 males), and 246
healthy control subjects (127 males) were collected. In
the patients group, epilepsy type was generalized in
188 patients and focal in 91 patients. Eighty-one sub-
jects (29.0%) showed slight to moderate MR or addi-
tional neuropsychiatric features (Table 1). The initial
survey led to the identification of 182 CNVs (58 in
patients with epilepsy, 74 in control subjects with MR,
and 50 in healthy control subjects) (data available on
request). Among these, 92 CNVs (ie, 28 in 26 patients
with epilepsy, 48 in 45 control subjects with MR, and
16 in 16 healthy control subjects) were absent in the
Database of Genomic Variants and were further fol-
lowed up (Table 2). The overall rate of rare CNVs in
patients with epilepsy (9.3%) was similar to that in
healthy control subjects (6.5%) (P=.26) and signifi-
cantly lower than that in control subjects with MR
(17.0%) (P=.01). Power estimates, calculated on the
frequency of rare CNVs in the control population,
indicate that the available sample can detect at least a
2.1-fold increase in the frequency of rare CNVs among
patients.
GENOMIC REARRANGEMENTS IDENTIFIED
IN PATIENTS WITH EPILEPSY
AND CONTROL SUBJECTS
A total of 28 rare CNVs were identified in 26 patients
with epilepsy (9.3%; 16 males) (Figure and Table 2).
No recurrent CNVs were found except for the
22q13.32qter deletion (cases C012 and B004). Locus
19q13.43 was deleted in 1 case (case A022) and dupli-
cated as part of a larger rearrangement in another one
(case A211). Twenty-four CNVs (92.3%) involved a
single chromosomal segment (12 deletions, 12 dupli-
cations), whereas the other 2 involved various seg-
ments in the same (case A096) or different (case
A164) chromosomes. The CNVs varied in size from
0.12 to 13 megabases (Mb). Likewise, the number of
rearranged genes varied from 1 to more than 100
(Table 2). Two duplications composed a single gene
(cases C106 and A049). The parental origin of the
rearrangements was assessed in 21 patients: 10
occurred de novo, 9 were inherited from a healthy
parent (5 paternal, 4 maternal), and 2 resulted
from unbalanced segregation of parental balanced
rearrangements. Altogether, de novo CNVs were larger
(P= .03) and showed higher gene content (P= .006)
compared with those inherited, whereas the type of
CNV (deletions vs duplications) did not differ
between the 2 groups (P=.17).
The clinical features of individuals carrying these
CNVs are shown in Table 3. Age at epilepsy onset
ranged from 3 months to 18 years (mean [SD], 7.1
[5.0] years). Epilepsy was generalized in 16 subjects
and focal in 10. Fourteen patients (53.8%) had MR,
and 10 of these had MR associated with autistic tracts
or attention-deficit/hyperactivity disorder. Nine
patients (34.6%) showed rearrangements that have
been already associated with microdeletion or micro-
duplication syndromes (Figure). These rearrange-
ments compared with the novel ones were more fre-
quently deletions (7 of 8 vs 5 of 17, respectively;
P=.03) and larger in size (mean, 5.2 vs 1.9 Mb, respec-
tively; P=.04), whereas they did not differ in gene con-
tent (mean, 45.8 vs 20.0 genes, respectively; P=.13) or
parental origin (de novo vs inherited, respectively;
P= .07). No newly identified CNVs matched those
reported in the DECIPHER database.
Among 246 ethnically matched healthy control
subjects, we identified 16 unreported CNVs (3 dele-
tions, 13 duplications) (Table 2). Largely overlapping
6q22.31 deletion (case 02957M) and 9p21.2 duplica-
tion (case 01503M) were identified in patients (cases
I091 and E011), indicating 2 novel, recurrent, poly-
morphic CNVs.
TheCNVs identified in patients comparedwith healthy
control subjects were larger (mean, 3.04 vs 0.79 Mb, re-
spectively;P=.03) and showedhigher gene content (mean,
31.3 vs 7.1 genes, respectively; P=.02), whereas the type
of unbalance (deletions vs duplications, respectively) did
not differ between the 2 groups (P=.06). TheCNVs larger
than 1 Mb (P=.002) and including more than 10 genes
(P=.005) occurred more frequently in patients than in
healthy control subjects. Conversely, the 2 groups did
not differ for CNVs smaller than 1 Mb (P=.05) and in-
volving 10 or fewer genes (P=.55).
Genotype-phenotype correlations indicated that
having MR or neuropsychiatric features was signifi-
cantly associated with the occurrence of CNVs com-
pared with not having them (14 of 81 cases [17.2%] vs
16 of 246 cases [6.5%], respectively; P=.004), whereas
epilepsy type (focal vs generalized; P=.52) was not. In
addition, CNVs in patients with epilepsy who have
MR or neuropsychiatric features were larger (P=.02)
Table 1. Demographic Data of 279 Patients With Epilepsy
of Unknown Cause
Characteristic Value
Sex, No.
Male 152
Female 127
Age, mean (range), y
At last evaluation 39.5 (2-69)
At epilepsy onset 15.9 (0.08-38)
Epilepsy type, No.
Generalized 188
Focal 91
Mental retardation or neuropsychiatric
features, No. (%)
Absent 198 (71.0)
Present 81 (29.0)
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and showed higher gene content (P .001) compared
with healthy control subjects, whereas the size and
gene content of CNVs identified in patients without
MR or neuropsychiatric features did not differ from
those in healthy control subjects.
The incidence of CNVs in patients with epilepsy
who have MR or neuropsychiatric features and in con-
trol subjects with MR is similar (45 of 265 cases
[17.0%] vs 14 of 81 cases [17.2%]; P .99). Likewise,
the 2 groups did not differ in CNV size (mean, 4.51 vs
3.78 Mb, respectively; P=.54) or gene content (mean,
37.8 vs 29.7 genes, respectively; P=.43). Among CNVs
identified in control subjects with MR, 3 were also
observed in the epilepsy group. The 6q22.31 duplica-
tion has been also detected in 2 control subjects with
MR. The 15q24.1 deletion was identified in a patient
with epilepsy showing different types of generalized
seizures plus mild MR with hyperactivity and in a con-
trol individual with moderate nonsyndromic MR. The
16p13.11 deletion was detected in a mentally healthy
patient with idiopathic generalized epilepsy (case
I104) and a control subject with MR showing moder-
ate MR and slight dysmorphisms.
CNV VALIDATION
A set of 17 rearrangements identified in patients with epi-
lepsywere validated by an independent assay, ie, the 244K
array-CGH (cases C012, B004, C106, and A049), fluo-
rescence in situ hybridization (cases C049, A096, C045,
A018, A164, A139, A066, A211, and A022), or quanti-
tative polymerase chain reaction (cases A181 and A002
and controls 14F and 18F). Validation assays confirmed
the occurrence of CNVs in all of the cases (data avail-
able on request).
BIOINFORMATIC ANALYSIS OF GENES
INCLUDED WITHIN CNVS
A total of 791 geneswere involved in rearrangements iden-
tified in patients (data available on request).We classified
the rearranged genes according to the putative biological
role attributed by the GO database, and we searched for a
significant enrichment of specificGOcategory usingGene-
Codis version2.0.A total of 593 geneswere associatedwith
at least 1 GO annotation (Table 4). Genes encoding ion
channels (P=.01) were the most significantly enriched
Table 2. Genomic Rearrangements Detected in Patients With Epilepsy
Patient No./
Sex
Copy Number Variation
Type Chromosome Cytoband Start, bp Stop, bp Size, bp Genes, No. Inheritance
Disease-Associated Rearrangements
C049/M Deletion 6 q26-q27 163 760 006 170 734 168 6 974 162 39 De novo
A096/F Deletion 8 p23.3-p23.1 181 330 7 290 797 7 109 467
111 Maternal balanced inversion
Duplication 8 p23.1-p21.2 12 627 430 24 549 176 11 921 746
A133/F Deletion 9 q34.3 137 776 611 140 128 884 2 352 273 81 De novo
C070/M Duplication 15 q11-q13.1 19 109 122 26 164 760 7 055 638 33 De novo
C045/Ma Deletion 15 q24.1-q24.3 72 253 337 75 747 080 3 493 743 54 De novo
I104/Ma Deletion 16 p13.11 14 851 860 16 183 756 1 331 896 17 Paternal
C012/M Deletion 22 q13.31-q13.33 46 139 271 49 526 339 3 387 068 45 De novo
B004/F Deletion 22 q13.32-q13.33 47 710 690 49 526 339 1 815 649 38 De novo
A040/F Deletion X p22.31 6 560 955 7 992 261 1 431 306 4 Maternal
Novel Rearrangements
A181/M Duplication 2 p12 76 930 522 78 641 030 1 710 508 2 Paternal
A002/F Duplication 2 q11.2 96 143 158 97 387 872 1 244 714 29 Paternal
A018/M Deletion 4 q31.23 149 164 064 150 453 131 1 289 067 2 Maternal
C106/F Duplication 6 q16.1 93 932 682 94 349 214 416 532 1 Paternal
A191/F Duplication 6 q22.2 117 129 742 117 953 435 823 693 7 Maternal
I091/Ma,b Duplication 6 q22.31 123 581 123 124 208 500 627 377 2 Undetermined
A164/M Duplication 7 q36.3 156 123 654 158 388 155 2 264 501
47 Paternal balanced translocation
Deletion 14 q32.33 103 375 996 106 312 055 2 936 059
E011/Mb Duplication 9 p21.2 26 790 566 27 940 168 1 149 602 10 Maternal
A139/F Deletion 9 q13-q21.13 70 341 355 76 692 922 6 351 567 26 De novo
A066/M Deletion 10 p12.33-p12.31 18 271 821 21 110 683 2 838 862 8 Paternal
I090/M Duplication 12 q24.33 130 430 446 131 708 300 1 277 854 8 Undetermined
B061/M Duplication 15 q26.1 88 129 144 88 253 691 124 547 4 Undetermined
A049/F Duplication 17 q24.3 65 681 113 67 198 174 1 517 061 1 Undetermined
A154/M Deletion 19 p13.3 1 162 440 1 377 123 214 683 12 De novo
A211/M Duplication 19 q13.41-q13.43 57 706 964 62 901 136 5 194 172 178 De novo
A022/M Deletion 19 q13.43 60 896 815 62 036 957 1 140 142 28 De novo
I100/F Duplication X p11.3 45 364 645 46 537 389 1 172 744 4 Undetermined
Abbreviation: bp, base pairs.
aDetected in control subjects with mental retardation only.
bDetected in healthy control subjects.
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among rearranged genes. In addition, significant associa-
tions were detected for genes involved in posttransla-
tional modification of proteins (P=.01), cell differentia-
tion (P=.02), and metabolic processes (P=.02) (Table 4).
GeneCodis analysis performed on 1327 genes (1116 with
GO identification) rearranged in control subjectswithMR
revealed a significant enrichment of genes involved in de-
velopment (P=.004), signal transduction (P=.005),meta-
bolic processes (P=.008), and cell differentiation (P=.008)
(Table 4). By contrast, we did not find any overrepre-
sented GO category in healthy control subjects.
COMMENT
Recent studies have shown that recurrent rearrange-
ments such as 15q11.2, 15q13.3, and 16p13.11 micro-
deletions represent a risk factor for a wide spectrum of
epilepsies.8-11 However, the role of nonrecurrent ge-
nomic rearrangements in patients with epilepsy of un-
known cause is still unclear and the diagnostic impact
of high-resolution screening of CNVs has not yet been
assessed.
We showed that the cumulative incidence of rare
CNVs is not significantly higher in patients with epi-
lepsy of unknown cause compared with a healthy con-
trol population. However, CNVs identified in patients
are larger and include more genes on average; in addi-
tion, rearrangements larger than 1 Mb and containing
10 or more genes are significantly overrepresented
among patients with epilepsy. These data indicate that
only a subgroup of rare CNVs play a role in the etiol-
ogy of epilepsy.
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Figure. Ideograms of chromosomes showing neurological microdeletions or microduplications syndromes (left) and copy number variations identified in our
study (right). Red bars indicate duplications; blue bars, deletions; AD, Alzheimer disease; ADLD, autosomal dominant leukodystrophy; ATR-16, -thalassemia
retardation associated with chromosome 16; CAA, cerebral amyloid angiopathy; CMT1A, Charcot-Marie-Tooth disease, type 1A; HNPP, hereditary neuropathy with
liability to pressure palsies; RCAD, renal cysts and diabetes; TAR, thrombocytopenia-absent radius; and WAGR, Wilms tumor, aniridia, genitourinary anomalies,
and mental retardation.
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It should be emphasized that CNV detection is largely
dependent on the type of platform (array-CGH vs single-
nucleotide polymorphism genotyping), the density and
design of the array, and the setting of analytic para-
meters.16 Most population-based CNV surveys have been
performed by single-nucleotide polymorphism arrays,
whereas array-CGH has become the elective routine di-
agnostic tool to identify genomic rearrangements in pa-
Table 3. Clinical Data of Patients With Epilepsy and Genomic Rearrangements
Patient No./
Sex/Age, y
Epilepsy Features
Epilepsy
Diagnosis
Mental
Status
Neuropsychiatric
Features CNV
Onset Follow-up Last Examination
Age
Seizure
Type
Other
Seizure
Type (Age
at Onset, y)
Previous
Therapy
Seizure
Frequency
Current
Therapy
Patients With Known Rearrangements
C049/M/27 15 y CPS TCS (16) NA 4/y VPA Cryptogenic
focal
Mild MR NA del(6)(q26qter)
A096/F/37 12 y FS, CPS TCS (12) CBZ, LEV Monthly TPM, OXC Cryptogenic
focal
Moderate
MR
Autistic tracts invdup
del(8)(qter→
p23.1::p23.1→
p21.2)
A133/F/5 2 y sGTCS,
CPS
NA VPA Monthly OXC Cryptogenic
focal
Moderate
MR
NA del(9)(q34.3qter)
C070/M/28 6 mo TCS Atonic (6) CBZ, OXC,
FLB,
TPM
Daily VPA, CNZ,
LTG
Cryptogenic
generalized
Moderate
MR
Autistic tracts dup(15)(q11q13.1)
C045/M/18 11 y TCS Atonic, tonic
(13)
NA 1 y VPA, LEV Cryptogenic
generalized
Mild MR Hyperactivity del(15)(q24.1q24.3)
I104/M/28 12 y Myoclonic TCS (12) NA Seizure
free
VPA Idiopathic
generalized
Healthy NA del(16)(p13.11)
C012/M/12 6 y Absences NA NA Daily VPA Cryptogenic
generalized
Mild MR Autistic tracts del(22)(q13.31qter)
B004/F/10 2 y FS, TCS NA NA 3 y VPA Cryptogenic
generalized
Moderate
MR
Hyperactivity del(22)(q13.32qter)
A040/F/10 1 y TCS Myoclonic (6),
TCS (15)
PB Monthly VPA, FLB Cryptogenic
generalized
Moderate
MR
Autistic tracts del(X)(p22.31)
Patients With Novel Rearrangements
A181/M/12 6 y Absences NA NA Seizure
free
VPA Cryptogenic
generalized
Mild MR ADHD dup(2)(p12)
A002/F/6 3 mo Tonic,
clonic
NA PB Weekly TPM Cryptogenic
generalized
Mild MR NA dup(2)(q11.2)
A018/M/17 13 y CPS NA NA 4 y VPA Cryptogenic
focal
Borderline NA del(4)(q31.23)
C106/F/29 5 y Absences,
TCS
Atonic (15) PB, CBZ,
CNZ
2 y TPM, LTG,
VPA
Cryptogenic
generalized
Borderline NA dup(6)(q16.1)
A191/M/29 10 y SPS CPS, sGTCS
(10)
CBZ, PB Monthly TPM, LTG,
VPA
Cryptogenic
focal
Borderline NA dup(6)(q22.2)
I091/M/12 10 y FS, TCS TCS (10) NA Seizure
free
VPA Idiopathic
generalized
Healthy NA dup(6)(q22.31)
A164/M/21 13 y CPS NA NA Seizure
free
CBZ Cryptogenic
focal
Moderate
MR
ADD der(14)t(7;14)
(q36.3;q32.33)
E011/M/24 9 y Absences NA NA Seizure
free
VPA Idiopathic
generalized
Healthy NA dup(9)(p21.2)
A139/F/14 4 y FS,
absences
TCS (4) NA Seizure
free
VPA, ETS Cryptogenic
generalized
Mild MR NA del(9)(q13q21.13)
A066/M/24 2 y SPS CPS (6), TCS
(17)
PB Monthly CBZ Cryptogenic
focal
Mild MR Autistic tracts del(10)(p12.33p12.31)
I090/M/28 18 y TCS NA NA Seizure
free
VPA Idiopathic
generalized
Healthy NA dup(12)(q24.33)
B061/M/11 1 y CPS, TCS NA VPA Monthly CBZ, LEV Cryptogenic
focal
Borderline Hyperactivity dup(15)(q26.1)
A049/F/16 8 y TCS Absences (8) PB 1 y VPA, ETS Idiopathic
generalized
Healthy NA dup(17)(q24.3)
A154/M/6 3 y FS, TCS NA VPA Seizure
free
NA Cryptogenic
generalized
Mild MR NA del(19)(p13.3)
A211/M/8 6 y CPS NA NA 1 y VPA Cryptogenic
focal
Healthy NA dup(19)
(q13.41q13.43)
A022/M/19 7 y CPS NA NA Seizure
free
CBZ, LTG Cryptogenic
focal
Borderline NA del(19)(q13.43)
I100/F/15 3 y Absences TCS (4),
myoclonic
(15)
NA Seizure
free
NA Idiopathic
generalized
Healthy NA dup(X)(p11.3)
Abbreviations: ADD, attention-deficit disorder; ADHD, attention-deficit/hyperactivity disorder; CBZ, carbamazepine; CNV, copy number variation;
CNZ, clonazepam; CPS, complex partial seizures; ETS, ethosuximide; FLB, felbamate; FS, febrile seizures; LEV, levetiracetam; LTG, lamotrigine; MR, mental
retardation; NA, not applicable; OXC, oxcarbazepine; PB, phenobarbital; sGTCS, secondarily generalized tonic-clonic seizures; SPS, simple partial seizures;
TCS, tonic-clonic seizures; TPM, topiramate; VPA, valproate sodium.
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tients.17 We identified 2 previously unreported CNVs in
both patients and control subjects, indicating that recur-
rent polymorphic CNVsmay have beenmissed by large-
scale population single-nucleotide polymorphism–
based studies. Accordingly,CNVscreening should include
appropriate internal controls, and heterogeneous data
from a public database such as the Database of Genomic
Variants should be considered with caution within a di-
agnostic context.
Our cohort includes patients referred to third-level cen-
ters for different epilepsy types of variable severity in the
absence of severe MR, major neuropsychiatric disease,
or pathognomonic dysmorphisms. These patients rep-
resent a common heterogeneous phenotypic group, rais-
ing complex diagnostic and management issues.
Genotype-phenotype correlations revealed that the fre-
quency of rare CNVs as well as their size and gene con-
tent are significantly higher in patients showing mild to
moderate MR or other minor neuropsychiatric features
than in healthy control subjects. On the other hand, the
incidence, size, and gene content of rare CNVs in pa-
tients with epilepsy who have healthy or borderlinemen-
tal status are not increased compared with our healthy
control population. Notably, comparative analysis of
CNVs identified in patientswith epilepsy and control sub-
jects with MR revealed a minor overlap, suggesting the
involvement of specific pathogeneticmechanisms for epi-
lepsy. Althoughwe cannot exclude that this lack of over-
lap is due to a sampling issue, analysis of putative bio-
logical processes related to rearranged genes pointed out
the specific role of ion channel genes in the epilepsy group.
In this scenario, the analysis of genomic rearrange-
ments emerges as a first-line diagnostic test for patients
with epilepsy showing MR and/or neuropsychiatric fea-
tures, even if mild.
BROADENING THE SPECTRUM
OF EMERGING SYNDROMES
About one-third of the patients showed rearrangements
that can be unambiguously considered pathogenetic. In
these cases, epilepsywas the predominant phenotypic ex-
pression of emerging microdeletion or microduplica-
tion syndromes, such as 6q terminal deletion (case
C049),18,19 invdupdel(8p) (case A096),20 9q34qter dele-
tion (case A133),21 15q11-q13 duplication (case C070),22
15q24 deletion (case C045),23 16p13.11 deletion (case
I104),24 22q13.3 deletion (cases C012 and B004),25 and
Xp22.31 deletion (caseA040).26 These syndromes are usu-
ally characterized by complex syndromic phenotypes in-
cluding dysmorphisms, brain structural abnormalities,
or multiple congenital defects. Conversely, our patients
showed amild clinical expression featuringmild tomod-
erate MR, no coarse facial features, and no structural ab-
normalities in the brain or other organs and could not
be diagnosedon clinical grounds. Theheterogeneous clini-
cal expressivity of these syndromes may be due to sev-
eral factors. Phenotypic differences among affected in-
dividuals may be explained by the parental origin of the
rearrangement (15q11-q13 duplication)22 or differ-
ences in the size of the rearranged region (15q24
deletion).23 Variable phenotypic expressivitymay also be
due to other factors such as unmasking of recessive mu-
tations, somatic mosaicism, and epigenetic or environ-
mental modifiers.17,27
NOVEL REARRANGEMENTS
The assessment of the pathogenetic effect of novel,
unreported rearrangements remains an open issue. The
de novo origin of a rearrangement is considered an
important predictor.17,27 Most of the novel rearrange-
ments identified in this study were transmitted from
unaffected parents. However, population studies indi-
cate that the de novo origin of a CNV does not neces-
sarily imply a pathogenetic effect.17,27 Consistently, in
our series, known pathogenetic and novel CNVs do not
differ for the parental origin. Moreover, rearrangements
inherited from a healthy parent cannot always be con-
sidered a benign variation. Indeed, it was recently dem-
onstrated that CNVs may represent susceptibility alleles
for a number of neuropsychiatric disorders, including
idiopathic epilepsy.8-11
The size, the type (deletions vs duplications), and the
number of genes involved in CNVs represent key fac-
tors underlying pathogenesis.27 In our series, novel CNVs
Table 4. Biological Processes Associated With Genes Rearranged in Patients and Control Subjects
GO Identification No.
Total Rearranged Genes
With GO Annotations, No.
Total Reference Genes
With GO Annotations, No.
Corrected
P Value
Patients with epilepsy (n=593) (n=29 095)
GO:0006811, ion transport 23 510 .01
GO:0006464, protein modification process 10 148 .01
GO:0030154, cell differentiation 20 483 .02
GO:0008152, metabolic process 20 482 .02
Healthy control subjects
No significant association
Control subjects with MR (n=1116) (n=29 095)
GO:0007275, multicellular organismal development 56 898 .004
GO:0007165, signal transduction 100 1872 .005
GO:0008152, metabolic process 33 482 .008
GO:0030154, cell differentiation 35 483 .008
Abbreviations: GO, Gene Ontology; MR, mental retardation.
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are more frequently duplications and are smaller com-
paredwith known pathogenetic rearrangements, whereas
the gene content is not significantly different. More-
over, we detected a tight link between themode of trans-
mission and the size and gene content of CNVs. Indeed,
inherited rearrangements were smaller and showed lower
gene content compared with de novo rearrangements. In
this scenario, mode of transmission, type, size, and gene
content of a novel CNV should be evaluated together to
assess its pathogenetic relevance.
EMERGING EPILEPTOGENIC PATHWAYS
A comprehensive bioinformatic analysis on CNVs iden-
tified in our cohort showed significant enrichment of ion
transport genes, confirming that the impairment of neu-
ronal ion currents represents a common pathophysi-
ologicalmechanism in epilepsy.1,2,5 In addition, our analy-
sis revealed a significant enrichment of genes involved
in cell differentiation andmetabolism. This finding is con-
sistent with emerging evidence pinpointing the role of
earlymaturation processes,28 subtle cytoarchitectural de-
fects,29,30 and metabolic impairment31 in the etiology of
epilepsies lacking detectable brain abnormalities. The im-
plication of developmental and metabolic processes in
control subjects with MR provides further evidence of a
pathogenetic link between epilepsy andMR.On the other
hand, the implication in patients with epilepsy of path-
ways related to posttranscriptional modification of pro-
teins in epilepsy cannot be readily interpreted.
CONCLUSIONS
Patients with epilepsy have a significantly increased bur-
den of large, rare, gene-rich CNVs, particularly when as-
sociated with MR or other neuropsychiatric features. Ac-
cordingly, we suggest that CNV screening should be
performed for diagnostic purposes preferentially in such
patients. Rearrangements smaller than 100 to 200kb could
have beenmissed in our study. However, small rearrange-
ments involving few genes were usually inherited from
healthy parents and have an uncertain clinical relevance.
Therefore, the implementation of very high-resolution
screening in clinical practice deserves caution.
Accepted for Publication: September 12, 2011.
Published Online: November 14, 2011. doi:10.1001
/archneurol.2011.1999
AuthorAffiliations:Muscular andNeurodegenerativeDis-
eases Unit and Laboratory of Neurogenetics (Drs P.
Striano, Robbiano, Traverso, Pezzella, Falace, Gazzerro,
and Zara and Mr Minetti) and Epidemiology and Statis-
tics Unit (Dr Galasso), Institute G. Gaslini, University
of Genova, and Laboratory of Genetics, Ente Ospe-
daliero Ospedali Galliera (Drs Paravidino, Malacarne,
Cavani, Dagna Bricarelli, and Coviello), Genova, Epi-
lepsy Center, Federico II University (Drs Coppola and
S. Striano) and Medical Genetics, Azienda Ospedaliera
di RilievoNazionale “A.Cardarelli” (DrCavaliere),Napoli,
Ospedale “S. Anna,” Como (Dr Belcastro), Epilepsy Cen-
tre, San Donato Hospital, Arezzo (Dr Bianchi), Unit of
Neurology (Dr Elia) and Laboratory of Genetics (Dr
Fichera), Oasi Institute for Research onMental Retarda-
tion and Brain Aging, Troina, Institute of Neurology,
Magna Græcia University, Catanzaro and Regional Epi-
lepsy Centre, Reggio Calabria (Dr Ferlazzo), Division of
Child Neurology, Institute “C. Besta,”Milano (Dr Freri),
Child Neurology and Psychiatry Unit, Maggiore Hospi-
tal, Bologna (Dr Gobbi), Dipartimento di Scienze Pedi-
atriche, University of Torino, Torino (Drs Molinatto,
Ferrero, and Silengo), Biologia Generale e Genetica
Medica, Università di Pavia, Pavia (Dr Zuffardi), Dipar-
timentoMaterno Infantile, Università di Palermo, Palermo
(Drs Benelli and Magi), and Diagnostic Genetic Unit,
Careggi Hospital, Firenze (Dr Piccione), Italy; and Ge-
netic and Laboratory Medicine, Geneva University Hos-
pitals, Geneva, Switzerland (Dr Gimelli).
Correspondence:Federico Zara, PhD, Laboratory ofNeu-
rogenetics, Department of Neuroscience, Institute G.
Gaslini, LargoGaslini 5,Genova 16147, Italy (federicozara
@ospedale-gaslini.ge.it).
Author Contributions: Acquisition of data: P. Striano,
Coppola, Paravidino, Malacarne, Gimelli, Robbiano,
Traverso, Pezzella, Belcastro, Bianchi, Elia, Falace,
Gazzerro, Ferlazzo, Freri, Galasso, Gobbi, Molinatto,
Cavani, Zuffardi, S. Striano, Ferrero, Silengo, Cavaliere,
Benelli,Magi, Piccione,DagnaBricarelli, Coviello, Fichera,
Minetti, and Zara. Critical revision of the manuscript for
important intellectual content: P. Striano, Coppola,
Paravidino, Malacarne, Gimelli, Robbiano, Traverso,
Pezzella, Belcastro, Bianchi, Elia, Falace, Gazzerro,
Ferlazzo, Freri, Galasso, Gobbi, Molinatto, Cavani,
Zuffardi, S. Striano, Ferrero, Silengo, Cavaliere, Benelli,
Magi, Piccione, Dagna Bricarelli, Coviello, Fichera,
Minetti, and Zara. Statistical analysis: P. Striano and Zara.
Obtained funding: Zara.Administrative, technical, and ma-
terial support: Coppola, Robbiano, and Zara.
Financial Disclosure: None reported.
Funding/Support: This work was supported in part by
thePierfranco andLuisaMariani Foundation.DrP. Striano
received the Italian Paediatrics Association Prize 2009 for
his research on “Application of Novel Genomics Tech-
nologies for Diagnosis of Patients With Epilepsy.”
Additional Contributions: The Collaborative Group on
Genetics of the Italian League Against Epilepsy pro-
vided helpful discussion of data.
REFERENCES
1. Baulac S, BaulacM. Advances on the genetics of Mendelian idiopathic epilepsies.
Clin Lab Med. 2010;30(4):911-929.
2. Pal DK, Pong AW, Chung WK. Genetic evaluation and counseling for epilepsy.
Nat Rev Neurol. 2010;6(8):445-453.
3. Cavalleri GL, Weale ME, Shianna KV, et al. Multicentre search for genetic sus-
ceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control
study. Lancet Neurol. 2007;6(11):970-980.
4. Koolen DA, Pfundt R, de Leeuw N, et al. Genomic microarrays in mental retar-
dation: a practical workflow for diagnostic applications. Hum Mutat. 2009;
30(3):283-292.
5. Gurnett CA, Hedera P. New ideas in epilepsy genetics: novel epilepsy genes, copy
number alterations, and gene regulation. Arch Neurol. 2007;64(3):324-
328.
6. Cook EH Jr, Scherer SW. Copy-number variations associated with neuropsychi-
atric conditions. Nature. 2008;455(7215):919-923.
7. McMullan DJ, Bonin M, Hehir-Kwa JY, et al. Molecular karyotyping of patients
ARCH NEUROL /VOL 69 (NO. 3), MAR 2012 WWW.ARCHNEUROL.COM
329
©2012 American Medical Association. All rights reserved.
Downloaded From: http://archneur.jamanetwork.com/ by a Universita Torino User  on 01/13/2016
with unexplained mental retardation by SNP arrays: a multicenter study. Hum
Mutat. 2009;30(7):1082-1092.
8. Helbig I, Mefford HC, Sharp AJ, et al. 15q13.3 microdeletions increase risk of
idiopathic generalized epilepsy. Nat Genet. 2009;41(2):160-162.
9. de Kovel CG, Trucks H, Helbig I, et al. Recurrent microdeletions at 15q11.2 and
16p13.11 predispose to idiopathic generalized epilepsies. Brain. 2010;133(pt 1):
23-32.
10. Heinzen EL, Radtke RA, Urban TJ, et al. Rare deletions at 16p13.11 predispose
to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet. 2010;
86(5):707-718.
11. Mefford HC, Muhle H, Ostertag P, et al. Genome-wide copy number variation in
epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies.
PLoS Genet. 2010;6(5):e1000962.
12. Commission on Classification and Terminology of the International League Against
Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes.
Epilepsia. 1989;30(4):389-399.
13. Ottman R, Barker-Cummings C, Leibson CL, Vasoli VM, Hauser WA, Buchhalter
JR. Validation of a brief screening instrument for the ascertainment of epilepsy.
Epilepsia. 2010;51(2):191-197.
14. Itsara A, Cooper GM, Baker C, et al. Population analysis of large copy number
variants and hotspots of human genetic disease. Am J Hum Genet. 2009;84
(2):148-161.
15. Carmona-Saez P, ChagoyenM, Tirado F, Carazo JM, Pascual-Montano A. GENE-
CODIS: a web-based tool for finding significant concurrent annotations in gene
lists. Genome Biol. 2007;8(1):R3.
16. Cooper GM, Zerr T, Kidd JM, Eichler EE, Nickerson DA. Systematic assessment
of copy number variant detection via genome-wide SNP genotyping. Nat Genet.
2008;40(10):1199-1203.
17. Lee C, Iafrate AJ, Brothman AR. Copy number variations and clinical cytoge-
netic diagnosis of constitutional disorders. Nat Genet. 2007;39(7)(suppl):S48-
S54.
18. Elia M, Striano P, Fichera M, et al. 6q terminal deletion syndrome associated with
a distinctive EEG and clinical pattern: a report of five cases. Epilepsia. 2006;
47(5):830-838.
19. Striano P, Malacarne M, Cavani S, et al. Clinical phenotype and molecular char-
acterization of 6q terminal deletion syndrome: five new cases. Am J Med Genet
A. 2006;140(18):1944-1949.
20. Shimokawa O, Kurosawa K, Ida T, et al. Molecular characterization of inv dup
del(8p): analysis of five cases. Am J Med Genet A. 2004;128A(2):133-137.
21. Stewart DR, Kleefstra T. The chromosome 9q subtelomere deletion syndrome.
Am J Med Genet C Semin Med Genet. 2007;145C(4):383-392.
22. Orrico A, ZollinoM, Galli L, Buoni S, Marangi G, Sorrentino V. Late-onset Lennox-
Gastaut syndrome in a patient with 15q11.2-q13.1 duplication. Am JMed Genet
A. 2009;149A(5):1033-1035.
23. Sharp AJ, Selzer RR, Veltman JA, et al. Characterization of a recurrent 15q24
microdeletion syndrome. Hum Mol Genet. 2007;16(5):567-572.
24. Hannes FD, Sharp AJ, Mefford HC, et al. Recurrent reciprocal deletions and du-
plications of 16p13.11: the deletion is a risk factor for MR/MCA while the dupli-
cation may be a rare benign variant. J Med Genet. 2009;46(4):223-232.
25. Phelan MC. Deletion 22q13.3 syndrome. Orphanet J Rare Dis. 2008;3:14.
26. Van Esch H, Hollanders K, Badisco L, et al. Deletion of VCX-A due to NAHR plays
a major role in the occurrence of mental retardation in patients with X-linked
ichthyosis. Hum Mol Genet. 2005;14(13):1795-1803.
27. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal mi-
croarray is a first-tier clinical diagnostic test for individuals with developmental
disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749-764.
28. Zhou YD, Lee S, Jin Z, Wright M, Smith SE, Anderson MP. Arrested maturation
of excitatory synapses in autosomal dominant lateral temporal lobe epilepsy.Nat
Med. 2009;15(10):1208-1214.
29. de Nijs L, Le´on C, Nguyen L, et al. EFHC1 interacts with microtubules to regulate
cell division and cortical development. Nat Neurosci. 2009;12(10):1266-
1274.
30. Falace A, Filipello F, La Padula V, et al. TBC1D24, an ARF6-interacting protein, is
mutated in familial infantile myoclonic epilepsy. Am J Hum Genet. 2010;87
(3):365-370.
31. Suls A, Mullen SA, Weber YG, et al. Early-onset absence epilepsy caused by mu-
tations in the glucose transporter GLUT1. Ann Neurol. 2009;66(3):415-419.
ARCH NEUROL /VOL 69 (NO. 3), MAR 2012 WWW.ARCHNEUROL.COM
330
©2012 American Medical Association. All rights reserved.
Downloaded From: http://archneur.jamanetwork.com/ by a Universita Torino User  on 01/13/2016
